Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1993 |
Name | rectum cancer |
Definition | A colorectal cancer that is located_in the rectum. |
Source | DiseaseOntology.org |
Alt Ids | DOID:1989 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer rectum cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01274624 | Phase I | Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Pelareorep | Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01309126 | Phase III | Cetuximab Cetuximab + PGG beta-glucan | Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | Terminated | USA | FRA | DEU | 1 |
NCT01740648 | Phase I | Fluorouracil + Trametinib | Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer | Completed | USA | 0 |
NCT01966289 | Phase I | Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine | SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | Completed | USA | 0 |
NCT01985763 | Phase Ib/II | Genistein Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Genistein in Treatment of Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02041481 | Phase I | Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02199236 | Phase I | Capecitabine + Fluorouracil | Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management | Completed | USA | 0 |
NCT02399813 | Phase Ib/II | ADXS11-001 | Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum | Completed | USA | 0 |
NCT02508077 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT03127098 | Phase Ib/II | ETBX-011 + Nogapendekin alfa inbakicept | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | Terminated | USA | 0 |
NCT03152370 | Phase I | E7046 + Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + E7046 | Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1) | Completed | USA | POL | GBR | 0 |
NCT03317119 | Phase I | Trametinib + Trifluridine-tipiracil hydrochloride | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03516708 | Phase Ib/II | Pembrolizumab Epacadostat Capecitabine + Oxaliplatin | Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | Recruiting | USA | 0 |
NCT03770689 | Phase Ib/II | Capecitabine Capecitabine + Peposertib | Phase Ib/II Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer | Completed | USA | ESP | 0 |
NCT03829410 | Phase Ib/II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation | Completed | USA | 0 |
NCT04124601 | Phase II | Capecitabine Capecitabine + Ipilimumab + Nivolumab | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (CHINOREC) | Completed | AUT | 0 |
NCT04293419 | Phase II | Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC) | Recruiting | ESP | 0 |
NCT04294160 | Phase I | Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | Terminated | USA | NLD | ISR | GBR | ESP | DEU | CAN | BEL | AUS | 1 |
NCT04486378 | Phase II | Autogene cevumeran | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Recruiting | USA | SWE | GBR | ESP | DEU | CAN | BEL | 0 |
NCT04926324 | Phase Ib/II | Dostarlimab-gxly + Niraparib | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Suspended | USA | 0 |
NCT05197322 | Phase II | Pembrolizumab | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) | Recruiting | GBR | 0 |
NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Recruiting | USA | 0 |
NCT05723562 | Phase II | Dostarlimab-gxly | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT05732389 | Phase II | Ipilimumab + Nivolumab | Immunotherapy in Patients With Early dMMR Rectal Cancer (RESET-R) | Recruiting | DNK | 0 |
NCT05912075 | Phase I | ASTX-660 + Fluorouracil + Leucovorin + Oxaliplatin ASTX-660 + Capecitabine + Oxaliplatin ASTX-660 + Capecitabine ASTX-660 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Preoperative Radiotherapy And ASTX660 in Rectum Cancer (PRAAR1) | Recruiting | FRA | 0 |
NCT06130826 | Phase I | M5A-IL2 | Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer | Recruiting | USA | 0 |